Kolb H J
GSF-National Research Center for Environment and Health, Klinikum Grosshadern, University Munich, Germany.
Vox Sang. 1998;74 Suppl 2:321-9. doi: 10.1111/j.1423-0410.1998.tb05438.x.
Allogeneic bone marrow transplantation is an effective treatment of leukemia. Intensive chemo- and radiotherapy used for conditioning and T-cells of the graft contribute to the control of leukemia. Animal experiments indicate that transfusion of lymphocytes from the marrow donor convert into complete chimerism without producing graft-versus-host disease, if delayed for two months or more. Transfusion of donor leukocytes (DLT) after marrow transplantation has induced lasting remissions in the majority of patients with chronic myelogenous leukemia (CML) in hematological or cytogenetic relapse, some patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), transformed phase CML and multiple myeloma (MMY). The mechanism of the graft-versus-leukemia reaction is discussed.
异基因骨髓移植是白血病的一种有效治疗方法。用于预处理的强化化疗和放疗以及移植物中的T细胞有助于控制白血病。动物实验表明，如果延迟两个月或更长时间，输注来自骨髓供体的淋巴细胞可转化为完全嵌合体而不产生移植物抗宿主病。骨髓移植后输注供体白细胞（DLT）已使大多数血液学或细胞遗传学复发的慢性粒细胞白血病（CML）患者、一些急性髓性白血病（AML）、骨髓增生异常综合征（MDS）、转化期CML和多发性骨髓瘤（MMY）患者获得持久缓解。文中讨论了移植物抗白血病反应的机制。
